Abstract

    Open Access Review Article Article ID: IJCEM-5-140

    Therapeutic options for advanced thyroid cancer

    Apoorva Jayarangaiah, Gurinder Sidhu, Jordonna Brown, Odeth Barrett-Campbell, Gul Bahtiyar, Irini Youssef, Shalini Arora, Samara Skwiersky and Samy I McFarlane*

    Thyroid cancer can be largely classifi ed as well-differentiated, poorly differentiated, medullary and anaplastic. Differentiated thyroid cancer (DTC) includes follicular and papillary subtypes, with the incidence of papillary thyroid cancer (PTC) on the rise. The mainstay of treatment for DTC includes a combination of surgery, radioactive iodine (RAI) and levothyroxine suppression. DTC portends a favorable prognosis, even in the presence of distant metastases, with a 50% rate of 5-year survival largely due to tumor cell’s sensitivity to RAI therapy infl uencing disease outcome. In radioactive iodine refractory differentiated thyroid cancer (RAI-refractory DTC) there is a lower survival rate prompting the use of other therapeutic options available.

    Keywords:

    Published on: Sep 9, 2019 Pages: 26-34

    Full Text PDF Full Text HTML DOI: 10.17352/ijcem.000040
    Get Citation Base Search Scilit OAI-PMH ResearchGate GrowKudos CrossMark

    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on IJCEM